With 51322.0 shares changed hands, the volume of the stock remained lighter than its average volume of 99020.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.981 whereas the lowest price it dropped to was $0.9. The 52-week range on GDTC shows that it touched its highest point at $3.68 and its lowest point at $0.89 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at -0.14.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GDTC was down-trending over the past week, with a drop of -27.77%, but this was down by -41.15% over a month. Three-month performance dropped to -57.63% while six-month performance fell -52.88%. The stock lost -28.58% in the past year, while it has lost -57.63% so far this year.
Float and Shares Shorts:
At present, 11.54 million GDTC shares are outstanding with a float of 4.04 million shares on hand for trading. On 2025-12-31, short shares totaled 21050.0, which was 18.000000999999997 higher than short shares on 1764288000. In addition to Mr. Chee Kong Choo as the firm’s Executive Chairman, Dr. Jieming Zeng M.D., Ph.D. serves as its Chief Scientific & Medical Officer and Director.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.15 being high and -$0.15 being low. For GDTC, this leads to a yearly average estimate of -$0.15.
